Subscribe to RSS
DOI: 10.1055/s-0031-1279826
Churg-Strauss Syndrome: Clinical Symptoms, Complementary Investigations, Prognosis and Outcome, and Treatment
Publication History
Publication Date:
14 June 2011 (online)
ABSTRACT
Churg-Strauss syndrome (CSS), first described in 1951, is a rare vasculitis of small- and medium-sized vessels. It is characterized by a constant association with asthma and eosinophilia, and by the presence of anti-myeloperoxidase (MPO) anti-neutrophil cytoplasmic antibodies (ANCA) in ~40% of the patients. Vasculitis typically develops in a previously asthmatic and eosinophilic middle-aged patient and most frequently involves the peripheral nerves and skin. Other organs, however, may be affected and must be screened for vasculitis, especially those associated with a poorer prognosis, such as the heart, kidney, and gastrointestinal tract, as assessed by the recently revised Five-Factor Score (FFS). Overall survival of CSS patients is excellent, but relapses are not uncommon and require maintenance or steroid-sparing therapies, depending on the original FFS-based prognosis at diagnosis. All patients require corticosteroids, often for prolonged periods, combined with immunosuppressants [e.g., induction (cyclophosphamide) and maintenance therapy (azathioprine)], for those with poorer prognoses. Recent insights, especially concerning clinical differences associated with ANCA status, showed that CSS patients might constitute a heterogeneous group, both clinically and pathogenically. Future therapies might reflect these differences more strongly.
KEYWORDS
Churg-Strauss syndrome - vasculitis - ANCA - steroids - immunosuppressants
REFERENCES
- 1 Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951; 27 (2) 277-301
- 2 Masi A T, Hunder G G, Lie J T et al.. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990; 33 (8) 1094-1100
- 3 Jennette J C, Falk R J, Andrassy K et al.. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 1994; 37 (2) 187-192
- 4 Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999; 78 (1) 26-37
- 5 Sablé-Fourtassou R, Cohen P, Mahr A French Vasculitis Study Group et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005; 143 (9) 632-638
- 6 Sinico R A, Di Toma L, Maggiore U et al.. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005; 52 (9) 2926-2935
- 7 Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. French Vasculitis Study Group (FVSG) . The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011; 90 (1) 19-27
- 8 Lanham J G, Elkon K B, Pusey C D, Hughes G R. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984; 63 (2) 65-81
- 9 Guillevin L, Amouroux J, Arbeille B, Boura R. Churg-Strauss angiitis: arguments favoring the responsibility of inhaled antigens. Chest. 1991; 100 (5) 1472-1473
- 10 Manger B J, Krapf F E, Gramatzki M et al.. IgE-containing circulating immune complexes in Churg-Strauss vasculitis. Scand J Immunol. 1985; 21 (4) 369-373
- 11 Bottero P, Bonini M, Vecchio F et al.. The common allergens in the Churg-Strauss syndrome. Allergy. 2007; 62 (11) 1288-1294
- 12 Falk R J, Terrell R S, Charles L A, Jennette J C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990; 87 (11) 4115-4119
- 13 Xiao H, Heeringa P, Hu P et al.. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002; 110 (7) 955-963
- 14 Heeringa P, Brouwer E, Tervaert J W, Weening J J, Kallenberg C G. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int. 1998; 53 (2) 253-263
- 15 Tsukadaira A, Okubo Y, Kitano K et al.. Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc. 1999; 20 (1) 39-44
- 16 Tai P C, Holt M E, Denny P, Gibbs A R, Williams B D, Spry C J. Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome. Br Med J (Clin Res Ed). 1984; 289 (6442) 400-402
- 17 Schmitt W H, Csernok E, Kobayashi S, Klinkenborg A, Reinhold-Keller E, Gross W L. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum. 1998; 41 (3) 445-452
- 18 Peen E, Hahn P, Lauwers G, Williams Jr R C, Gleich G, Kephart G M. Churg-Strauss syndrome: localization of eosinophil major basic protein in damaged tissues. Arthritis Rheum. 2000; 43 (8) 1897-1900
- 19 Cottin V, Tardy F, Gindre D, Vernet G, Deviller P, Cordier J F. Urinary eosinophil-derived neurotoxin in Churg-Strauss syndrome. J Allergy Clin Immunol. 1995; 96 (2) 261-264
- 20 Higashi N, Mita H, Taniguchi M et al.. Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides. J Allergy Clin Immunol. 2004; 114 (6) 1353-1358
- 21 Kiene M, Csernok E, Müller A, Metzler C, Trabandt A, Gross W L. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum. 2001; 44 (2) 469-473
- 22 Taki H, Shinoda K, Hounoki H et al.. Serum interleukin-5 levels correlate with disease activity of Churg-Strauss syndrome in a patient treated with a leucotriene receptor antagonist, pranlukast, and inhaled corticosteroid. Scand J Rheumatol. 2010; 39 (4) 341-343
- 23 Termeer C, Simon J C, Schöpf E. Churg-Strauss syndrome associated with fluticasone therapy. Arch Dermatol. 2001; 137 (11) 1527-1528
- 24 Terrier B, Bièche I, Maisonobe T et al.. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood. 2010; 116 (22) 4523-4531
- 25 Müschen M, Warskulat U, Perniok A et al.. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol. 1999; 155 (3) 915-925
- 26 Polzer K, Karonitsch T, Neumann T et al.. Eotaxin-3 is involved in Churg-Strauss syndrome—a serum marker closely correlating with disease activity. Rheumatology (Oxford). 2008; 47 (6) 804-808
- 27 Hellmich B, Csernok E, Gross W L. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005; 1051 121-131
- 28 Pagnoux C. Churg-Strauss syndrome: evolving concepts. Discov Med. 2010; 9 (46) 243-252
- 29 Saito H, Tsurikisawa N, Tsuburai T, Akiyama K. Involvement of regulatory T cells in the pathogenesis of Churg-Strauss syndrome. Int Arch Allergy Immunol. 2008; 146 (suppl 1) 73-76
- 30 Saito H, Tsurikisawa N, Tsuburai T, Oshikata C, Akiyama K. Cytokine production profile of CD4 + T cells from patients with active Churg-Strauss syndrome tends toward Th17. Int Arch Allergy Immunol. 2009; 149 (suppl 1) 61-65
- 31 Wieczorek S, Holle J U, Bremer J P et al.. Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener's granulomatosis and Churg-Strauss syndrome. Rheumatology (Oxford). 2010; 49 (5) 907-914
- 32 Wieczorek S, Holle J U, Epplen J T. Recent progress in the genetics of Wegener's granulomatosis and Churg-Strauss syndrome. Curr Opin Rheumatol. 2010; 22 (1) 8-14
- 33 Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004; 51 (1) 92-99
- 34 Haugeberg G, Bie R, Bendvold A, Larsen A S, Johnsen V. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol. 1998; 17 (5) 364-368
- 35 Martin R M, Wilton L V, Mann R D. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf. 1999; 8 (3) 179-189
- 36 Watts R A, Lane S E, Bentham G, Scott D G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000; 43 (2) 414-419
- 37 Watts R A, Lane S, Scott D G. What is known about the epidemiology of the vasculitides?. Best Pract Res Clin Rheumatol. 2005; 19 (2) 191-207
- 38 Harrold L R, Andrade S E, Go A S et al.. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol. 2005; 32 (6) 1076-1080
- 39 Dietz A, Hübner C, Andrassy K. Macrolide antibiotic-induced vasculitis (Churg-Strauss syndrome) [in German]. Laryngorhinootologie. 1998; 77 (2) 111-114
- 40 Imai H, Nakamoto Y, Hirokawa M, Akihama T, Miura A B. Carbamazepine-induced granulomatous necrotizing angiitis with acute renal failure. Nephron. 1989; 51 (3) 405-408
- 41 Mathur S, Dooley J, Scheuer P J. Quinine induced granulomatous hepatitis and vasculitis. BMJ. 1990; 300 (6724) 613
- 42 Guillevin L, Guittard T, Blétry O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung. 1987; 165 (3) 165-172
- 43 Green R L, Vayonis A G. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet. 1999; 353 (9154) 725-726
- 44 Franco J, Artés M J. Pulmonary eosinophilia associated with montelukast. Thorax. 1999; 54 (6) 558-560
- 45 Wechsler M E, Drazen J M. Zafirlukast and Churg-Strauss syndrome. Chest. 1999; 116 (1) 266-267
- 46 Wechsler M E, Finn D, Gunawardena D et al.. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000; 117 (3) 708-713
- 47 Wechsler M E, Wong D A, Miller M K, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009; 136 (2) 507-518
- 48 Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007; 144 (2) 155-158
- 49 Puéchal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med. 2008; 19 (5) 364-366
- 50 Hauser T, Mahr A, Metzler C et al.. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008; 63 (8) 677-682
- 51 Wechsler M E, Pauwels R, Drazen J M. Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?. Drug Saf. 1999; 21 (4) 241-251
- 52 Chumbley L C, Harrison Jr E G, DeRemee R A. Allergic granulomatosis and angiitis (Churg-Strauss syndrome): report and analysis of 30 cases. Mayo Clin Proc. 1977; 52 (8) 477-484
- 53 Gaskin G, Clutterbuck E J, Pusey C D. Renal disease in the Churg-Strauss syndrome: diagnosis, management and outcome. Contrib Nephrol. 1991; 94 58-65
- 54 Haas C, Geneau C, Odinot J M et al.. Angéïte allergique et granulomateuse: le syndrome de Churg–Strauss: Étude rétrospective de 16 cas. Ann Med Interne (Paris). 1991; 142 (5) 335-342
- 55 Abu-Shakra M, Smythe H, Lewtas J, Badley E, Weber D, Keystone E. Outcome of polyarteritis nodosa and Churg-Strauss syndrome: an analysis of twenty-five patients. Arthritis Rheum. 1994; 37 (12) 1798-1803
- 56 Riva N, Cerri F, Butera C et al.. Churg Strauss syndrome presenting as acute neuropathy resembling Guillain Barré syndrome: case report. J Neurol. 2008; 255 (11) 1843-1844
- 57 Guillevin L, Lhote F, Gayraud M et al.. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore). 1996; 75 (1) 17-28
- 58 Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005; 84 (2) 115-128
- 59 Cottin V, Cordier J F. Eosinophilic pneumonias. Allergy. 2005; 60 (7) 841-857
- 60 Bhagirath K M, Paulson K, Ahmadie R, Bhalla R S, Robinson D, Jassal D S. Clinical utility of cardiac magnetic resonance imaging in Churg-Strauss syndrome: case report and review of the literature. Rheumatol Int. 2009; 29 (4) 445-449
- 61 Marmursztejn J, Cohen P, Duboc D et al.. Cardiac magnetic resonance imaging in Churg-Strauss-syndrome: impact of immunosuppressants on outcome assessed in a prospective study on 8 patients. Clin Exp Rheumatol. 2010; 28 (1, suppl 57) 8-13
- 62 Marmursztejn J, Vignaux O, Cohen P et al.. Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. Clin Exp Rheumatol. 2009; 27 (1, suppl 52) S70-S76
- 63 Androudi S, Iaccheri B, Brazitikos P, Papadaki T, Foster C S. Bilateral chronic anterior uveitis & neuro-ophthalmologic manifestations in a patient with Churg-Strauss syndrome: an unusual ocular presentation. Ocul Immunol Inflamm. 2004; 12 (1) 59-63
- 64 Fernandez A J. Ureteral granuloma in Churg-Strauss syndrome. Mayo Clin Proc. 1978; 53 (9) 618
- 65 Modigliani R, Muschart J M, Galian A, Clauvel J P, Piel-Desruisseaux J L. Allergic granulomatous vasculitis (Churg-Strauss Syndrome): report of a case with widespread digestive involvement. Dig Dis Sci. 1981; 26 (3) 264-270
- 66 Généreau T, Lortholary O, Pottier M A French Vasculitis Study Group et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. Arthritis Rheum. 1999; 42 (12) 2674-2681
- 67 Lie J T, Bayardo R J. Isolated eosinophilic coronary arteritis and eosinophilic myocarditis: a limited form of Churg-Strauss syndrome. Arch Pathol Lab Med. 1989; 113 (2) 199-201
- 68 Lie J T. Limited forms of Churg-Strauss syndrome. Pathol Annu. 1993; 28 (Pt 2) 199-220
- 69 Steinfeld S, Golstein M, De Vuyst P. Chronic eosinophilic pneumonia (CEP) as a presenting feature of Churg-Strauss syndrome (CSS). Eur Respir J. 1994; 7 (11) 2098
- 70 Terrier B, Saadoun D, Sene D et al.. Anti-myeloperoxidase antibodies are a useful marker of disease activity in ANCA-associated vasculitides. Ann Rheum Dis. 2008; 68 1564-1578
- 71 Wallaert B, Gosset P, Prin L, Bart F, Marquette C H, Tonnel A B. Bronchoalveolar lavage in allergic granulomatosis and angiitis. Eur Respir J. 1993; 6 (3) 413-417
- 72 Finan M C, Winkelmann R K. The cutaneous extravascular necrotizing granuloma (Churg-Strauss granuloma) and systemic disease: a review of 27 cases. Medicine (Baltimore). 1983; 62 (3) 142-158
- 73 Reid A J, Harrison B D, Watts R A, Watkin S W, McCann B G, Scott D G. Churg-Strauss syndrome in a district hospital. QJM. 1998; 91 (3) 219-229
- 74 Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med. 2003; 54 169-184
- 75 Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951; 27 (2) 277-301
- 76 Hoffman G S, Kerr G S, Leavitt R Y et al.. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116 (6) 488-498
- 77 Cohen P, Pagnoux C, Mahr A French Vasculitis Study Group et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007; 57 (4) 686-693
- 78 Bourgarit A, Le Toumelin P, Pagnoux C French Vasculitis Study Group et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore). 2005; 84 (5) 323-330
- 79 Ribi C, Cohen P, Pagnoux C French Vasculitis Study Group et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008; 58 (2) 586-594
- 80 Guillevin L. Clinical trials on systemic necrotizing vasculitides. Presse Med. 2010; 39 (6) 653-659
- 81 Gayraud M, Guillevin L, Cohen P French Cooperative Study Group for Vasculitides et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol. 1997; 36 (12) 1290-1297
- 82 Metzler C, Hellmich B, Gause A, Gross W L, de Groot K. Churg Strauss syndrome—successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol. 2004; 22 (6, suppl 36) S52-S61
- 83 Pagnoux C, Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes?. Curr Opin Rheumatol. 2010; 22 (1) 21-28
- 84 Koukoulaki M, Smith K G, Jayne D R. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis. 2006; 65 (4) 557-559
- 85 Pepper R J, Fabre M A, Pavesio C et al.. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008; 47 (7) 1104-1105
- 86 Bouldouyre M A, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis. 2009; 68 (4) 606
- 87 Metzler C, Schnabel A, Gross W L, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2008; 26 (3, suppl 49) S35-S40
- 88 Giavina-Bianchi P, Agondi R, Kalil J. One year administration of anti-IgE to a patient with Churg-Strauss syndrome. Int Arch Allergy Immunol. 2008; 146 (2) 176
- 89 Hamilos D L, Christensen J. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol. 1991; 88 (5) 823-824
- 90 Rutberg S A, Ward D E, Roth B J. Churg-Strauss syndrome and pregnancy: successful treatment with intravenous immunoglobulin. J Clin Rheumatol. 2002; 8 (3) 151-156
- 91 Taniguchi M, Tsurikisawa N, Higashi N et al.. Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int. 2007; 56 (2) 97-103
- 92 Jayne D R, Gaskin G, Rasmussen N European Vasculitis Study Group et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 18 (7) 2180-2188
- 93 Jayne D R, Gaskin G, Rasmussen N et al.. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 18 (7) 2180-2188
Loïc GuillevinM.D.
Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases (including Vasculitis, Scleroderma), INSERM U1060, Hôpital Cochin, Assistance Publique–Hôpitaux de Paris, Université Paris Descartes
27, rue du faubourg Saint-Jacques, 75679 Paris Cedex 14, France
Email: loic.guillevin@cch.aphp.fr